RxDoctor Payments Data

Patrick Hsu, MD

Cardiovascular Disease · Las Vegas, NVNPI 1962405027

Payments from drug & device makers

$2,415in general payments, 2019–2025

Across 52 payments — averaging $46.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$403
  • Cvrx, Inc.$360
  • Medtronic$269
  • Amarin Pharma, Inc.$216
  • Impulse Dynamics (USA) Inc.$191
  • Portola Pharmaceuticals, LLC$135
  • plus $841 from 13 others

What the payments were for

  • Food & beverage$2,29295%
  • Education$1225%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,415 in reported general payments places this provider in the 40th percentile of 165 cardiovascular disease providers in Nevada.

See all cardiovascular disease providers in Nevada

Medicare billing

Part B allowed, 2024
$631,037
Medicare patients
930
Services billed
5,896

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban306$410,963
XareltoRivaroxaban122$138,944
EntrestoSacubitril/Valsartan59$62,780
Repatha SureclickEvolocumab47$50,468
Repatha SyringeEvolocumab37$40,538
JardianceEmpagliflozin21$32,485
VascepaIcosapent Ethyl25$20,735
MounjaroTirzepatide16$18,426
Praluent PenAlirocumab14$17,224
NexletolBempedoic Acid11$7,583
Ezetimibe320$6,787
Dabigatran EtexilateDabigatran Etexilate Mesylate16$6,612
Metoprolol Succinate512$6,059
Atorvastatin Calcium777$5,831
Losartan Potassium480$3,858

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$28$138,944122 claims
NovartisEntresto$16$62,78059 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 165 cardiovascular disease providers in Nevada.

Other cardiovascular disease in Las Vegas

See the full list for Nevada

Where these figures come from

Is this you, or does something look wrong? →